Realigning incentives for developing and pricing new anticancer treatments

JAMA. 2011 Jun 8;305(22):2347-8. doi: 10.1001/jama.2011.793.
No abstract available

MeSH terms

  • Antineoplastic Agents / economics*
  • Centers for Medicare and Medicaid Services, U.S.
  • Cost Control
  • Cost Sharing*
  • Cost-Benefit Analysis
  • Drug Costs / trends*
  • Drug Discovery / economics*
  • Drug Industry*
  • Health Care Costs / trends
  • Humans
  • Male
  • Medicare / economics*
  • Models, Economic
  • Motivation*
  • Patient Protection and Affordable Care Act
  • Prostatic Neoplasms / drug therapy
  • United States

Substances

  • Antineoplastic Agents